featured
Carfilzomib or Bortezomib Plus Lenalidomide and Dexamethasone in Newly Diagnosed Multiple Myeloma
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
The Lancet Oncology
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Carfilzomib or Bortezomib in Combination With Lenalidomide and Dexamethasone for Patients With Newly Diagnosed Multiple Myeloma Without Intention for Immediate Autologous Stem-Cell Transplantation (ENDURANCE): A Multicentre, Open-Label, Phase 3, Randomised, Controlled Trial
Lancet Oncol 2020 Aug 28;[EPub Ahead of Print], SK Kumar, SJ Jacobus, AD Cohen, M Weiss, N Callander, AK Singh, TL Parker, A Menter, X Yang, B Parsons, P Kumar, P Kapoor, A Rosenberg, JA Zonder, E Faber, S Lonial, KC Anderson, PG Richardson, RZ Orlowski, LI Wagner, SV RajkumarFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.